-
Manufacturing, Supply Chain & Infrastructure4 weeks agoNovo faces delay in US review of haemophilia drug
The FDA has extended its review of Novo's experimental haemophilia A drug denecimig because of ongoing remediation work at a manufacturing facility.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoNovartis taps China’s Abogen for autoimmunity TCE
Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
-
AI, Machine Learning & Computational Biology4 weeks agoEverlywell rolls out Clairity AI for breast cancer in US
Digital health firm Everlywell is rolling out a Clairity AI, which can assess the risk of developing breast cancer from a mammogram, across the US.
-
Clinical Trials & Development4 weeks agoNew diabetes and obesity studies making waves at EASD
As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoUK puts £80m behind dementia diagnosis push
The UK is putting £80 million ($105 million) in funding behind nine technologies that it hopes will be able to diagnose dementia more quickly.
-
Capital, M&A & Industry Strategy4 weeks agoSpace pharma Varda raises $251m, and other financings
Varda has closed a $251m round to fuel its mission to make medicines in orbit, with TriGemX, Breye, AnaCardio, and ai3Bio also raising new funds.
-
Manufacturing, Supply Chain & Infrastructure1 month agoBayer names Christoph Koenen as its new CMO
Bayer has looked internally for its chief medical officer, appointing Christoph Koenen to the post alongside his current clinical development role.
-
Capital, M&A & Industry Strategy1 month agoSanofi forges new $8bn pact with Regeneron
Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new...
-
Global Biotechnology & Pharmaceutical Markets1 month agoGLOBE model finalised, with narrowed scope and fewer savings
CMS has finalised a new drug pricing policy for Medicare that has drawn sharp criticism from the pharma industry.
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agouniQure falls on long-term Huntington’s gene therapy data
uniQure's latest data drop for its gene therapy for Huntington's disease, under review in the US and UK, has spooked investors.
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
